Patents by Inventor David Huw Davies
David Huw Davies has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 10270352Abstract: A switching circuit, electrical energy converter, power management unit and energy harvesting system are described. Such apparatus is applicable to energy harvesting applications which involve a variety of transducers, either singly or simultaneously. The transducers may, for example, be photovoltaic, thermoelectric, piezoelectric, or electrodynamic. The described converters operate to convert impedances, voltages and currents. They incorporate inductive energy transfer elements, which are magnetically coupled. Different combinations of these energy transfer elements are used to obtain different conversion ratios, which can be referred to as “gears”. On the input side, having multiple gears enables easier and better matching to a wider variety of energy transducers. On the output side, it enables easier and better accommodation of a wider spread of energy storage voltages and of a wider variety of loads.Type: GrantFiled: September 4, 2017Date of Patent: April 23, 2019Assignee: Trameto LimitedInventors: Laurence Alan Strong, David Huw Davies, Christopher Julian Travis
-
Patent number: 10174311Abstract: Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.Type: GrantFiled: October 4, 2016Date of Patent: January 8, 2019Assignee: Immport Therapeutics, Inc.Inventors: Philip Felgner, David Huw Davies, Xiaowu Liang
-
Publication number: 20180069481Abstract: A switching circuit, electrical energy converter, power management unit and energy harvesting system are described. Such apparatus is applicable to energy harvesting applications which involve a variety of transducers, either singly or simultaneously. The transducers may, for example, be photovoltaic, thermoelectric, piezoelectric, or electrodynamic. The described converters operate to convert impedances, voltages and currents. They incorporate inductive energy transfer elements, which are magnetically coupled. Different combinations of these energy transfer elements are used to obtain different conversion ratios, which can be referred to as “gears”. On the input side, having multiple gears enables easier and better matching to a wider variety of energy transducers. On the output side, it enables easier and better accommodation of a wider spread of energy storage voltages and of a wider variety of loads.Type: ApplicationFiled: September 4, 2017Publication date: March 8, 2018Inventors: Laurence Alan Strong, David Huw Davies, Christopher Julian Travis
-
Publication number: 20170081659Abstract: Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.Type: ApplicationFiled: October 4, 2016Publication date: March 23, 2017Inventors: Philip Felgner, David Huw Davies, Xiaowu Liang
-
Publication number: 20160158344Abstract: Contemplated compositions, devices, and methods are drawn to various antigens from Herpes Simplex Virus type 1 (HSV-1) and Herpes Simplex Virus type 2 (HSV-2) and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.Type: ApplicationFiled: February 9, 2016Publication date: June 9, 2016Inventors: David Huw Davies, Xiaowu Liang, Philip Felgner
-
Patent number: 9297803Abstract: Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.Type: GrantFiled: November 1, 2007Date of Patent: March 29, 2016Assignees: Immport Therapeutics, Inc., Rutgers, The State University of New JerseyInventors: Philip Felgner, David Huw Davies, Xiaowu Liang, Maria Laura Gennaro
-
Publication number: 20150056241Abstract: Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.Type: ApplicationFiled: October 20, 2014Publication date: February 26, 2015Inventors: Philip Felgner, David Huw Davies, Xiaowu Liang
-
Publication number: 20150037367Abstract: Contemplated compositions, devices, and methods are drawn to various antigens from Herpes Simplex Virus type 1 (HSV-1) and Herpes Simplex Virus type 2 (HSV-2) and their use in vaccines, therapeutic agents, and various diagnostic tests. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.Type: ApplicationFiled: June 29, 2012Publication date: February 5, 2015Inventors: David Huw Davies, Xiaowu Liang, Philip Felgner
-
Publication number: 20140004141Abstract: Contemplated compositions, devices, and methods are drawn to various antigens from the pathogen T. gondii and their use in various diagnostic tests, vaccines, and therapeutic agents. In particularly preferred aspects, the antigens are immunodominant and have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and/or have a known association with a disease parameter.Type: ApplicationFiled: December 20, 2011Publication date: January 2, 2014Applicant: Immport Therapeutics, Inc.Inventors: David Huw Davies, Xiaowu Liang, Philip Felgner
-
Publication number: 20100119535Abstract: Contemplated compositions, devices, and methods comprise immunodominant antigens from selected human pathogens (Burkholderia pseudomallei, Borrelia burgdorferi, Brucella melitensis, Chlamydia muridarum, Coxiella burnetii, Francisella tularensis, human Herpes virus 1 and 2, Mycobacterium tuberculosis, Plasmodium falciparum, and Vaccinia virus) can be used as a vaccine, as diagnostic markers, and as therapeutic agents. In particularly preferred aspects, the antigens have quantified and known relative reactivities with respect to sera of a population infected with the pathogen, and have a known association with a disease parameter.Type: ApplicationFiled: November 1, 2007Publication date: May 13, 2010Applicant: IMMPORT THERAPEUTICS, INC.Inventors: Philip Felgner, David Huw Davies, Xiaowu Liang
-
Patent number: 7393533Abstract: The invention relates to, among other things, methods of protecting against poxvirus infection or pathogenesis and including pox viruses such as small pox (variola major and variola minor), cowpox, monkey pox vaccinia virus, and Molluscum Contagiosum using compositions such as human, humanized and chimeric antibodies that specifically bind to H3L protein.Type: GrantFiled: November 8, 2005Date of Patent: July 1, 2008Assignee: La Jolla Institute for Allergy and ImmunologyInventors: Shane Crotty, Philip L Felgner, David Huw Davies
-
Patent number: 6541491Abstract: Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CO—NH2— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a —S—S-dimer thereof when R2=H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy.Type: GrantFiled: November 30, 2000Date of Patent: April 1, 2003Assignee: Zeneca LimitedInventors: David Huw Davies, Francis Thomas Boyle, James Michael Wardleworth, Peter Wedderburn Kenny, Peter Beverley Scholes, Zbigniew Stanely Matusiak
-
Patent number: 6436691Abstract: Antibody Directed Enzyme Prodrug Therapy (ADEPT) systems for use in cancer based on mutated carboxypeptidase B (CPB) enzymes. Enzyme conjugates for ADEPT are substantially non-immunogenic in humans comprising a targeting moiety (for example an antibody) capable of binding with a tumor associated antigen, the targeting moiety being linked to a mutated form of a CPB enzyme capable of converting a prodrug into an antineoplastic drug wherein the prodrug is not significantly convertible into antineoplastic drug in humans by natural unmutated enzyme. A preferred enzyme mutant is human pancreatic CPB comprising a Lys or Arg residue at position 253. Suitable mustard prodrugs are disclosed in the specification.Type: GrantFiled: February 13, 1998Date of Patent: August 20, 2002Assignee: Zeneca LimitedInventors: Anthony Michael Slater, David Charles Blakey, David Huw Davies, John Frederick Hennam, Laurent Francois Andre Hennequin, Peter Robert Marsham, Robert Ian Dowell
-
Patent number: 6232338Abstract: Pharmaceutical compositions comprising an inhibitor of ras farnesylation of formula (I) wherein, R1 is for example H and further values as defined in the specification; R2 is for example H and further values as defined in the specification; R3 is for example H or a substituent having values as defined in the specification; p is 0-3 in which R3 values can be the same or different; L is a linking moiety for example —CO—NH2— and further values as defined in the specification; A is selected from phenyl; naphthyl; a 5-10 membered monocyclic or bicyclic heteroaryl ring containing up to 5 heteroatoms where the heteroatoms are independently selected from O, N and S; or a —S—S— dimer thereof when R2=H; or an enantiomer, diastereoisomer, pharmaceutically acceptable salt, prodrug or solvate thereof together with a pharmaceutically acceptable diluent or carrier. A particular use is cancer therapy.Type: GrantFiled: February 3, 1998Date of Patent: May 15, 2001Assignee: Zeneca LimitedInventors: David Huw Davies, Francis Thomas Boyle, James Michael Wardleworth, Peter Wedderburn Kenny, Peter Beverley Scholes, Zbigniew Stanely Matusiak
-
Patent number: 5985281Abstract: A two component system for therapeutic treatment of a host, having a first component comprising a targeting moiety capable of binding with a tumour associated antigen, linked to a mutated enzyme capable of converting a prodrug into an antineoplastic drug, and a second component comprising a prodrug convertible under the influence of the mutated enzyme to the antineoplastic drug. The mutated enzyme is a mutated form of a natural host enzyme which recognizes its natural substrate by an ion pair interaction with the substrate, wherein the mutated enzyme and prodrug have structures such that the polarity of the mutated enzyme/prodrug ion pair interaction is reversed relative to the natural host enzyme/natural substrate ion pair interaction. The first component is substantially non-immunogenic in the host and the prodrug second component is not significantly convertible into antineoplastic drug in the host by natural unmutated host enzyme.Type: GrantFiled: June 23, 1997Date of Patent: November 16, 1999Assignee: Zeneca LimitedInventors: Christopher John Taylorson, Hendrikus Johannes Eggelte, Antonio Tarragona-Fiol, Brian Robert Rabin, Francis Thomas Boyle, John Frederick Hennam, David Charles Blakey, Peter Robert Marsham, David William Heaton, David Huw Davies, Anthony Michael Slater, Laurent Francois Andre Hennequin
-
Patent number: 5953311Abstract: A method and apparatus are disclosed for determining the boundaries of guard intervals of data symbols being received in a coded orthogonal frequency division multiplexed signal. Temporal samples separated by an interval of an active interval of a data symbol are associated in pairs, and difference signals obtained. The dispersion of a first comparison block of difference signals is determined, and compared to the dispersion of a second comparison block of difference signals, the second comparison block being displaced from the first comparison block by n samples. An F ratio is calculated for the dispersions of the two blocks. F ratios are iterated in a succession of comparison blocks, and a signal representing the F ratios subjected to peak detection. The peaks represent the boundaries of the symbol's guard interval. This information is utilized in synchronizing an FFT window for subsequent signal reconstruction.Type: GrantFiled: February 18, 1997Date of Patent: September 14, 1999Assignee: Discovision AssociatesInventors: David Huw Davies, Jonathan Parker, Anthony Peter John Claydon
-
Patent number: 4085208Abstract: This invention relates to the preparation of novel 1-epi-aminoglycosides, useful as antibacterial agents, and also relates to the process for the preparation of known as well as novel 1-N-substituted aminoglycoside antibacterial agents.Type: GrantFiled: June 21, 1976Date of Patent: April 18, 1978Assignee: Schering CorporationInventors: Alan K. Mallams, David Huw Davies
-
Patent number: 4066752Abstract: This invention relates to the preparation of novel 1-desamino-1-oxo-aminoglycosides and their use as intermediates in the preparation of novel 1-desamino-1-hydroxy and 1-desamino-1-epi-hydroxyaminoglycoside antibacterial agents.Type: GrantFiled: June 21, 1976Date of Patent: January 3, 1978Assignee: Schering CorporationInventors: Alan K. Mallams, David Huw Davies
-
Patent number: 4009328Abstract: Aminoglycoside 66-40C, a minor product produced by the fermentation of Micromonospora inyoensis, is separated from said fermentation mixture, and is used as an intermediate in preparing the known antibiotic, sisomicin, as well as 6' -N-alkylsisomicins having antibacterial activity. Claimed are Aminoglycoside 66-40C as well as 6' -N-t-alkylsisomicins having a tertiary carbon bonded to the 6' -nitrogen.Type: GrantFiled: May 2, 1975Date of Patent: February 22, 1977Assignee: Schering CorporationInventors: Alan K. Mallams, Richard W. Tkach, David Huw Davies
-
Patent number: 3978214Abstract: The novel aminoglycoside, 0-2-amino-2,3,4-trideoxy-.alpha.-D-glycero-hex-4-enopyranosyl-(1.fwdarw.4) -garamine, is prepared by treating Aminoglycoside 66-40C with aqueous acid followed by treatment with a hydride donor reducing agent. Pharmaceutical compositions of the novel aminoglycoside and its pharmaceutically acceptable acid addition salts are described as well as their use as antiprotozoal agents.Type: GrantFiled: May 2, 1975Date of Patent: August 31, 1976Assignee: Schering CorporationInventors: Alan K. Mallams, David Huw Davies